GRAY
NASDAQGraybug Vision Inc.
News · 26 weeks10%
2025-12-212026-06-14
Mix090d
No activity.
Latest news
25 items- SECAmendment: SEC Form S-1/A filed by Graybug Vision Inc.S-1/A - Grayscale Investments, Inc. (0002073548) (Filer)
- PRAviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of DirectorsAviceda Therapeutics ("Aviceda"), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment car
- SECGraybug Vision Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - CalciMedica, Inc. (0001534133) (Filer)
- SECSEC Form EFFECT filed by Graybug Vision Inc.EFFECT - CalciMedica, Inc. (0001534133) (Filer)
- 13D/GSEC Form SC 13D/A filed by Graybug Vision Inc. (Amendment)SC 13D/A - CalciMedica, Inc. (0001534133) (Subject)
- 13D/GSEC Form SC 13G/A filed by Graybug Vision Inc. (Amendment)SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)
- 13D/GSEC Form SC 13G/A filed by Graybug Vision Inc. (Amendment)SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)
- INSIDERRoberts Eric W was granted 91,086 shares, increasing direct ownership by 449% to 111,373 units (SEC Form 4)4 - CalciMedica, Inc. (0001534133) (Issuer)
- 13D/GSEC Form SC 13D/A filed by Graybug Vision Inc. (Amendment)SC 13D/A - CalciMedica, Inc. (0001534133) (Subject)
- 13D/GSEC Form SC 13G filed by Graybug Vision Inc.SC 13G - CalciMedica, Inc. (0001534133) (Subject)
- 13D/GSEC Form SC 13G filed by Graybug Vision Inc.SC 13G - CalciMedica, Inc. (0001534133) (Subject)
- SECSEC Form S-3 filed by Graybug Vision Inc.S-3 - CalciMedica, Inc. (0001534133) (Filer)
- 13D/GSEC Form SC 13G filed by Graybug Vision Inc.SC 13G - CalciMedica, Inc. (0001534133) (Subject)
- 13D/GSEC Form SC 13G filed by Graybug Vision Inc.SC 13G - CalciMedica, Inc. (0001534133) (Subject)
- INSIDERSanderling Venture Partners Vi Lp bought $2,515,080 worth of shares (679,384 units at $3.70), increasing direct ownership by 35% to 946,744 units (SEC Form 4)4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERMiddleton Fred A bought $2,515,080 worth of shares (679,384 units at $3.70) (SEC Form 4)4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERLeheny A. Rachel was granted 91,086 shares, increasing direct ownership by 483% to 109,926 units (SEC Form 4)4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERWilson Robert N was granted 68,314 shares, increasing direct ownership by 38% to 250,475 units (SEC Form 4)4 - CalciMedica, Inc. (0001534133) (Issuer)
- SECGraybug Vision Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (Amendment)8-K/A - CalciMedica, Inc. (0001534133) (Filer)
- SECGraybug Vision Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - CalciMedica, Inc. (0001534133) (Filer)
- INSIDERWilson Robert N bought $1,670 worth of shares (506 units at $3.30), increasing direct ownership by 0.28% to 182,161 units (SEC Form 4)4 - CalciMedica, Inc. (0001534133) (Issuer)
- 13D/GSEC Form SC 13D/A filed by Graybug Vision Inc. (Amendment)SC 13D/A - CalciMedica, Inc. (0001534133) (Subject)
- SECSEC Form 10-Q filed by Graybug Vision Inc.10-Q - CalciMedica, Inc. (0001534133) (Filer)
- SECGraybug Vision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CalciMedica, Inc. (0001534133) (Filer)
- INSIDERLeheny A. Rachel bought $6,680 worth of shares (2,000 units at $3.34), increasing direct ownership by 12% to 18,840 units (SEC Form 4)4 - CalciMedica, Inc. (0001534133) (Issuer)
GRAY FAQ
6 questionsWhat does Graybug Vision Inc. do?
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a...Where does GRAY stock trade?
Graybug Vision Inc. (GRAY) is listed on NASDAQ.What sector and industry is GRAY in?
Graybug Vision Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Graybug Vision Inc. go public?
Graybug Vision Inc. (GRAY) completed its IPO in 2020.What companies are similar to GRAY?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare GRAY side-by-side with any of them on Quantisnow.How can I track GRAY on Quantisnow?
Quantisnow aggregates Graybug Vision Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GRAY to receive live email and push alerts on every new disclosure.